SOMERSET, N.J.—August 15, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its unaudited financial results for the three and six months ended June 30, 2023. In addition to financial performance, Legend Biotech reported on the success of its portfolio […]
SOMERSET, N.J.—August 3, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00am Eastern Time on Tuesday, August 15, 2023 to review second-quarter results. Company executives will provide an overview of Legend Biotech’s performance […]
SOMERSET, N.J.—June 6, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The sBLA seeks to expand the label for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) […]
SOMERSET, N.J.—June 5, 2023 — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that results from the Phase 3 CARTITUDE-4 study showed that, at a median follow up of 16 months, cilta-cel reduced the risk of disease progression or death […]
SOMERSET, N.J. – May 25, 2023 – Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that a Type II variation application was submitted to the European Medicines Agency (EMA) for CARVYKTI® based on data from the CARTITUDE-4 study (NCT04181827), which […]
Thank you for your interest in learning more about Legend Biotech.
media@legendbiotech.com
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.